Michael J. Schlosser, EVP and Chief Clinical Officer of HCA Healthcare, Inc., filed a Form 4 on November 6, 2026, disclosing the sale of 1,200 shares of HCA Healthcare common stock on November 4, 2026.

Key Highlights

  • Reporting person: Michael J. Schlosser, EVP and Chief Clinical Officer of HCA Healthcare, Inc. (NYSE:HCA)
  • Transaction: 1,200 shares of common stock disposed of (transaction code S) on November 4, 2026
  • Weighted average price: $494.6524 per share, with individual sales ranging from $494.63 to $494.70, inclusive
  • Direct holdings after transaction: 1,443.1027 shares held directly
  • Indirect holdings: 6,951 shares held indirectly via the 2022 Trust
  • Filing signed: Kevin A. Ball, Attorney-in-Fact, on November 6, 2026

Schlosser November 2026 Share Sale: Transaction Details

According to the filing, Schlosser disposed of 1,200 shares of HCA Healthcare common stock on November 4, 2026, at a weighted average price of $494.6524 per share. The filing noted that the shares were sold in multiple transactions at prices ranging from $494.63 to $494.70, inclusive. The filing further stated that Schlosser "undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."

Following the reported transaction, the filing disclosed that Schlosser directly holds 1,443.1027 shares of HCA Healthcare common stock. In addition, the filing reported 6,951 shares held indirectly through an entity identified as the 2022 Trust. No derivative securities transactions were reported in Table II of the filing.

The Form 4 was filed by one reporting person and was signed by Kevin A. Ball as Attorney-in-Fact on November 6, 2026. The filing does not indicate whether the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox was not checked.

What Was Disclosed

The filing disclosed the sale of 1,200 shares of HCA Healthcare common stock by EVP and Chief Clinical Officer Michael J. Schlosser on November 4, 2026, at a weighted average price of $494.6524, leaving him with 1,443.1027 shares held directly and 6,951 shares held indirectly via the 2022 Trust.